Fatal acquired coagulation factor V deficiency after hepatectomy for advanced hepatocellular carcinoma as a possible immune checkpoint inhibitor-related adverse event: a case report

BACKGROUND: Atezolizumab plus bevacizumab therapy was recently introduced as the first line for unresectable advanced hepatocellular carcinoma (HCC), but immune-related adverse events (IrAEs) due to atezolizumab are a great concern. Here, we report the case of a patient who developed fatal acquired...

Descripción completa

Detalles Bibliográficos
Autores principales: Arakaki, Shintaro, Ono, Shinichiro, Kawamata, Futoshi, Ishino, Shinichiro, Uesato, Yasunori, Nakajima, Tomo, Nishi, Yukiko, Morishima, Satoko, Arakaki, Shingo, Maeshiro, Tatsuji, Souri, Masayoshi, Ichinose, Akitada, Masuzaki, Hiroaki, Takatsuki, Mitsuhisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9895589/
https://www.ncbi.nlm.nih.gov/pubmed/36729240
http://dx.doi.org/10.1186/s40792-023-01601-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9895589/
https://www.ncbi.nlm.nih.gov/pubmed/36729240
http://dx.doi.org/10.1186/s40792-023-01601-2

Ejemplares similares